Canada markets open in 2 hours 9 minutes

Cidara Therapeutics, Inc. (CDTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
12.29+2.04 (+19.90%)
At close: 04:00PM EDT
14.92 +2.63 (+21.40%)
Pre-Market: 07:20AM EDT

Cidara Therapeutics, Inc.

6310 Nancy Ridge Drive
Suite 101
San Diego, CA 92121
United States
858 752 6170
https://www.cidara.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 69

Key Executives

NameTitlePayExercisedYear Born
Dr. Jeffrey L. Stein Ph.D.President, CEO & Executive Director603.7kN/A1955
Dr. Taylor SandisonChief Medical Officer497kN/A1972
Dr. Kevin M. Forrest Ph.D.Founder and Chief Strategy Officer333.31kN/A1977
Ms. Allison Lewis CCP, SPHRSenior Vice President of People & CultureN/AN/AN/A
Dr. Leslie Tari Ph.D.Chief Scientific Officer845.1kN/A1967
Ms. Laura A. NavaltaSenior Vice President of Clinical OperationsN/AN/AN/A
Dr. Nicole Davarpanah J.D., M.D.Senior VP of Translational Research & DevelopmentN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Corporate Governance

Cidara Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.